In a bid to boost its pipeline, Abpro has announced a collaboration with Celltrion for the co-development and commercialization of bispecific antibody, ABP-102. The deal, which is worth up to US$1.75 B, gives Celltrion access to Abpro’s technology platforms, DiverslmmuneTM and MultimabTM, to generate monoclonal antibody therapies for patients suffering from HER2+ cancer, including breast, gastric, and pancreatic cancer. The deal complements Celltrion’s existing oncology pipeline which includes Herceptin biosimilar, Herzuma® (trastuzumab).